Treatment prevents symptoms for majority of young boys with adrenoleukodystrophy, ALD
BALTIMORE, Md. (July 11, 2005) – Use of Lorenzo's Oil in young boys who have been diagnosed with but are not yet showing signs of a pediatric neurological disorder known as X-linked adrenoleukodystrophy (X-ALD) may prevent the disease from developing in the body. According to a study of male children published today in the Archives of Neurology, use of the oil prevented onset of the disease in a majority of cases. For the first time, the study demonstrated the preventive effects of Lorenzo's Oil using rigorous and scientifically-accepted research methods.
The study followed 89 boys ages seven and younger who tested positive for an abnormal gene that identifies X-ALD. Over a period of seven years, researchers treated the boys with daily oral doses of Lorenzo's Oil, a combination of two fats extracted from olive oil and rapeseed oil, and moderately restricted their dietary fat. All patients had a normal brain MRI and showed no neurological signs and symptoms of X-ALD prior to the study. At the completion of the study, nearly three-fourths (74 percent) of the 89 patients showed no signs of disease progression, demonstrating a significant preventive effect. Researchers correlated greater compliance with a lower risk of developing the disease.
"This clinical study clearly demonstrates that the use of Lorenzo's Oil can prevent the onset of the rapidly progressive and devastating form of the brain disease that affects 50 percent of boys with X-ALD," said Hugo Moser, M.D., Director of the Neurogenetics Research Center at the Kennedy Krieger Institute in Baltimore, Md., and lead author of the study. "This finding is an exciting progression of the research to which my associates and I have dedicated ourselves to help these children."
X-ALD affects 16,000 patients in the United States. The disease causes the breakdown of myelin, a fatty substance that acts as an insulator around nerve fibers. Symptoms appear between four and 10 years of age, and can lead to nerve deterioration, loss of verbal communication, strength and coordination and, eventually, complete breakdown of bodily function.
"The results of this trial offer clinical support for treating the many young boys identified at high-risk for the disease," said Gary Goldstein, M.D., CEO of the Kennedy Krieger Institute. "This advance results from truly collaborative efforts between researchers in the medical community, parents and advocates for these patients."
There is still no cure for X-ALD, and treatment options are limited to hormone therapy and bone marrow transplants. While these transplants can provide important long-term benefits to boys with X-ALD in whom brain involvement is still in the early stages, the procedure carries a significant risk of mortality and morbidity, and is not effective when brain involvement is already severe.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
Courage is being scared to death and saddling up anyway.
-- John Wayne